{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-24-000169","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.965595+00:00","generated_at":"2026-06-02T22:36:58.231125+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Artivion Q1 revenue $97.4M (+17% YoY); nets $7.5M income vs loss; raises FY24 guidance","bullets":["Revenue $97.4M, up 17% GAAP (16% constant currency) vs $83.2M in Q1 2023.","Net income $7.5M ($0.18 diluted EPS) vs net loss ($13.5M) in Q1 2023; non-GAAP net income $2.6M ($0.06 EPS).","Non-GAAP adjusted EBITDA rose 60% to $17.3M from $10.8M in Q1 2023.","Revised FY24 constant-currency revenue growth guidance to 9%-12% (prev 8%-12%); revenue range $386M-$396M.","Tissue processing +26% constant currency YoY; stent grafts +19%; Latin America +22% constant currency."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-24-000169","json":"https://secwatch.observer/filing/0000784199-24-000169.json","markdown":"https://secwatch.observer/filing/0000784199-24-000169.md","text":"https://secwatch.observer/filing/0000784199-24-000169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419924000169/0000784199-24-000169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419924000169/aort-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:36:58.231125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}